Trial · NCT05817669
Results by group51
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 51
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Meeting Overall CRESS Response of at Least 3 of 5 Items at Week 24 | Efgartigimod | 45.5 | 95% Confidence Interval 26.92 to 65.34 | Percentage of participants | |
| Percentage of Participants Meeting Overall CRESS Response of at Least 3 of 5 Items at Week 24 | Placebo | 11.1 | 95% Confidence Interval 1.99 to 43.50 | Percentage of participants | |
| Number of Participants With TEAEs, AESI, and SAEs | Efgartigimod | Any TEAE | 20 | Participants | |
| Number of Participants With TEAEs, AESI, and SAEs | Placebo | Any TEAE | 7 | Participants | |
| Number of Participants With TEAEs, AESI, and SAEs | Efgartigimod | Any AESI | 15 | Participants | |
| Number of Participants With TEAEs, AESI, and SAEs | Placebo | Any AESI | 5 | Participants | |
| Number of Participants With TEAEs, AESI, and SAEs | Efgartigimod | Any SAE | 1 | Participants | |
| Number of Participants With TEAEs, AESI, and SAEs | Placebo | Any SAE | 0 | Participants | |
| Percentage of Participants With MCII in ESSDAI at Week 24 | Efgartigimod | 72.7 | 95% Confidence Interval 51.85 to 86.85 | Percentage of participants | |
| Percentage of Participants With MCII in ESSDAI at Week 24 | Placebo | 55.6 | 95% Confidence Interval 26.67 to 81.12 | Percentage of participants | |
| Percentage of Participants With Low Disease Activity in ESSDAI at Week 24 | Efgartigimod | 59.1 | 95% Confidence Interval 38.73 to 76.74 | Percentage of participants | |
| Percentage of Participants With Low Disease Activity in ESSDAI at Week 24 | Placebo | 22.2 | 95% Confidence Interval 6.32 to 54.74 | Percentage of participants | |
| Percentage of Participants With MCII in clinESSDAI at Week 24 | Efgartigimod | 77.3 | 95% Confidence Interval 56.56 to 89.88 | Percentage of participants | |
| Percentage of Participants With MCII in clinESSDAI at Week 24 | Placebo | 77.8 | 95% Confidence Interval 45.26 to 93.68 | Percentage of participants | |
| Percentage of Participants With Low Disease Activity in clinESSDAI at Week 24 | Efgartigimod | 59.1 | 95% Confidence Interval 38.73 to 76.74 | Percentage of participants | |
| Percentage of Participants With Low Disease Activity in clinESSDAI at Week 24 | Placebo | 33.3 | 95% Confidence Interval 12.06 to 64.58 | Percentage of participants | |
| Percentage of Participants With MCII in ESSPRI at Week 24 | Efgartigimod | 31.8 | 95% Confidence Interval 16.36 to 52.68 | Percentage of participants | |
| Percentage of Participants With MCII in ESSPRI at Week 24 | Placebo | 33.3 | 95% Confidence Interval 12.06 to 64.58 | Percentage of participants | |
| Change From Baseline in ESSDAI Score at Week 24 | Efgartigimod | -5.0 | Inter-Quartile Range -10.0 to -4.0 | score on a scale | |
| Change From Baseline in ESSDAI Score at Week 24 | Placebo | -4.0 | Inter-Quartile Range -13.0 to -1.0 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05817669/results